Prazosin: Supply issue resolved

A new brand of prazosin is funded from 1 November 2021. There was a brief supply issue affecting this medicine.

Supply issue resolved

Arrotex Pharmaceuticals has advised that supply was shipped to wholesalers on 18 November 2021. 

18 months' supply secured

We have sourced 18 months’ supply of prazosin. The Apo-Prazosin S29 brand of prazosin will be funded from 1 November 2021. We are working to secure longer-term supply of prazosin.

The Apo-Prazosin S29 brand of prazosin is not Medsafe approved and will need to be supplied under section 29 of the Medicines Act.

Pharmacodes for Apo-Prazosin S29 tabs

  • 1 mg: 2625725
  • 2 mg: 2625733
  • 5 mg: 2625741

Restriction to existing patients removed

We had previously restricted prazosin to people who had been using it before 1 August 2021. This restriction will be removed from 1 November 2021. 

Key dates 

1 November 2021: New supply listed

  • Apo-Prazosin S29 listed
  • restriction to existing patients removed

1 May 2022: Apo-Prazosin delisted

  • The original Apo-Prazosin brand will be delisted. The S29 brand will be the only funded brand. 
  • Stock of Apo-Prazosin is expected to run out by late 2021.

Alternative product 

We have received clinical advice that doxazosin may be a suitable alternative for people to be transitioned to. 

Doxazosin monograph | NZ Formulary(external link)

Doxazosin listing | Pharmaceutical Schedule(external link)

Who to contact 

If you are taking prazosin, talk to your pharmacist or the person who prescribed the prazosin. They are in the best place to advise on your clinical circumstances. 

If you have funding questions about prazosin, email

Pharmac's response to Apotex's departure